Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 3,567

Document Document Title
WO/2006/127235
Clarified polyolefins such as polypropylene are used widely to make polymer articles, containers, and the like. Such articles may be manufactured by the injection of molten polymer into a mold or forming device in manufacturing processes...  
WO/2006/123726
A pharmaceutical composition comprising (a) a phosphodiesterase (PDE)-IV inhibitor or a pharmacologically acceptable salt thereof and (b) vitamin D or a vitamin D derivative or a pharmacologically acceptable salt thereof; a therapeutic a...  
WO/2006/124899
There are disclosed methods for producing derivatives of lactide, including lactamides, propylene glycol, esters, acid anhydrides, modified starches, acrylic acid and pyruvic acid. Also disclosed are methods for producing lactide. Use of...  
WO/2006/124899
There are disclosed methods for producing derivatives of lactide, including lactamides, propylene glycol, esters, acid anhydrides, modified starches, acrylic acid and pyruvic acid. Also disclosed are methods for producing lactide. Use of...  
WO/2006/121095
A pharmaceutical composition comprising a compound having the general formula (I) or a pharmacologically acceptable salt thereof as the active ingredient: (I) wherein R1 represents a C6-C10 aryl group which may be substituted by a residu...  
WO/2006/120755
Provided is a process for producing a cyclic acetal form of 3-oxocyclopentane-1-carboxylic acid more efficiently and industrially advantageously. The process for producing a cyclic acetal form of 3-oxocyclopentane-1-carboxylic acid repre...  
WO/2006/117611
The present patent application concerns new compounds of formula (I) with R1 and R2 taken together with the nitrogen atom to which they are attached, form a saturated nitrogen-containing ring, A is a saturated C1 -4 alkylene and B a C3-4...  
WO/2006/116158
Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided, wherein each of R1, R2, R3, R4, y, n, m, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of...  
WO/2006/114432
The invention pertains to a method for purifying glycolide comprising the step of distilling crude glycolide under reflux using a distillation column having a ratio S/CxL > 1.1 and S2/C2L > 0.4 m, wherein S stands for the inner surface o...  
WO/2006/114432
The invention pertains to a method for purifying glycolide comprising the step of distilling crude glycolide under reflux using a distillation column having a ratio S/CxL > 1.1 and S2/C2L > 0.4 m, wherein S stands for the inner surface o...  
WO/2006/110221
Various non-limiting embodiments disclosed herein relate to photochromic materials having extended pi-conjugated systems. For example, various non-limiting embodiments disclosed herein provide a photochromic material, such as an indeno-f...  
WO/2006/106241
The invention relates to a compound of formula (I) in which: R1, R2, R3, R4, while being identical or different, each represent an atom or group selected among H, halogen, alkyl, alkoxy, phenyl and cyano; X represents a bond, an oxygen a...  
WO/2006/103527
The present invention relates to an aromatic substituted pentadienoic acid amides and there use in combination of specific amounts of aromatic amides i.e. 4-alkyl-5-(substituted phenyl)-2(E),4(E)-pentadienoic acid amides, its geometrical...  
WO/2006/102760
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I); wherein Y, L, Z, W, X, Q, R1, R2 and R3 are as defined in the specification.  
WO/2006/098308
An anthranilic acid derivative represented by the general formula below or a salt thereof: wherein R1 and R2 independently represent a hydrogen atom or the like; R3 represents a phenyl, cycloalkyl or bicyclic heterocyclic group which may...  
WO/2006/095020
Compounds of the general formula (I) in which the meanings of the substituents R1 and R2 are as stated in claim 1, have renin-inhibiting properties and can be used as medicines.  
WO/2006/092623
A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R1 and R2 together form a group -(CH2)...  
WO/2006/085108
Therapeutically active anthranilic acid derivatives of Formula (I) wherein R1, R2, W, Y and Z are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compo...  
WO/2006/081276
Compounds of the formula where the variables have the meaning defined in the specification have analgesic and or immunostimulant effect in mammals.  
WO/2006/081332
The invention relates to 5-HT6 receptor antagonists. Novel arylamine compounds having the formula: (see formula I) and pharmaceutically acceptable salts and/or esters thereof, wherein - n is 0, 1, 2, 3, or 4; - A, when present is a lower...  
WO/2006/072189
Described are substituted spiro[bornyl-2,4'-(1,3-dioxanes)], a method for their production and fragrance compositions comprising them.  
WO/2006/072189
Described are substituted spiro[bornyl-2,4'-(1,3-dioxanes)], a method for their production and fragrance compositions comprising them.  
WO/2006/069656
The invention relates to compounds of the formula (I) in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as ...  
WO/2006/067466
The present invention pertains to certain pyrazines and pyridines, and dervatives thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the f...  
WO/2006/067466
The present invention pertains to certain pyrazines and pyridines, and dervatives thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the f...  
WO/2006/064611
ABSTRACT Disclosed is a process for purifying a hydroxycarboxylic acid, comprising: a crystallization step of subjecting a hydroxycarboxylic acid aqueous solution to crystallization for purification, a separation step of separating a hyd...  
WO/2006/062093
An anthranilic acid derivative represented by the general formula (X) [wherein R1 represents hydrogen or a carboxy-protecting group; R2 represents optionally substituted phenyl, a heterocyclic group, etc.; R3 represents optionally substi...  
WO/2006/061372
The invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action: serotonin reuptake inhibition and affinity for dopamine -D2 receptors and to methods for the preparation of these compounds. The invention...  
WO/2006/062110
A compound represented by the formula (I): [wherein R1 represents C3-9 branched alkyl; R2 represents, e.g., linear or branched, C2-9 alkyl optionally substituted by halogen, etc.; and X represents oxygen, etc.] (provided that the followi...  
WO/2006/058648
The present invention relates to compounds of Formula (I) wherein Ar, Ar2, R2, R3, R4, m, p and s are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and...  
WO/2006/050212
The present invention relates to compounds and pharmaceutically acceptable salts of formula I: which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compounds include inhibitors of...  
WO/2006/048620
Liquid crystal compounds of Formula (I) for use in liquid crystal devices contains a dioxatetralin unit within the mesogenic liquid crystal core. The dioxatetralin unit may be located at any position within the mesogenic core of the liqu...  
WO/2006/038606
Disclosed are a compound represented by the formula (I) below, a pharmaceutically acceptable salt thereof, a solvate of those, and a pharmaceutical composition containing such a compound. (In the formula, X1 represents N or CR2; X2 repre...  
WO/2006/034641
The present invention discloses a process for producing Simvastatin and intermediate thereof. The present invention uses inexpensive and available reagent, its condition is mild, and it leaves out the protective and deprotective steps wh...  
WO/2006/030892
The invention aims at providing a process for the production of NS-220 which is suitable for mass production on an industrial scale. The invention is constituted of (1) a process for the production of methyl cis-5-(4-chlorobutyl) -2-meth...  
WO/2006/028972
Mercaptoamide compounds, represented by Formulas (IA), (IB), (IIA), and (IIB): or a pharmaceutically acceptable salt thereof, inhibit histone deacetylase enzyme and are useful for the treatment and/or prevention of various infections, ca...  
WO/2006/024627
The N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 1, 2, 3, or 4; Z represents O, S, NR6, SO or SO2; R1 represent hydrogen, cyano, hydroxy, or C1-4alkyl optiona...  
WO/2006/024627
The N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 1, 2, 3, or 4; Z represents O, S, NR6, SO or SO2; R1 represent hydrogen, cyano, hydroxy, or C1-4alkyl optiona...  
WO/2006/021806
Compounds of formula (I) are useful in treatment of sleep disorders and other conditions mediated by 5-HT2A receptor activity.  
WO/2006/021805
Compounds of formula (I) are potent and selective antagonists of the human 5-HT2A receptor, and hence useful in treatment of a variety of adverse conditions of the CNS.  
WO/2006/022825
Various non-limiting embodiments disclosed herein related to photochromic materials comprising the reaction product of (a) at least one ring-opening cyclic monomer, and (b) a photochromic initiator. Other non-limiting embodiments related...  
WO/2006/018524
The invention relates to a novel method for the synthesis of 2,5-dioxane-1,4-diones having formula (I), comprising the oxidation of the ketone function of a cyclic compound having formula (II), wherein R1, R2, R3 and R4 independently rep...  
WO/2006/018855
Disclosed are novel compounds of general formula (I) where the symbols are as defined in the specification, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them...  
WO/2006/016708
Conventional many fungicidal compositions have had practical problems such that either a preventive effect or a curing effect is inadequate, the residual effect tends to be inadequate, or the controlling effect against plant diseases ten...  
WO/2006/012227
The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor MR, and pharmaceutical compositions thereof. The compounds of the invention can be useful in the tr...  
WO/2006/007634
The present invention relates to synthetic processes for the preparation of compounds bearing a dioxanyl moiety, in particular to compounds bearing a dioxanyl side chain attached to a mono- or polycyclic core moiety, more particularly a ...  
WO/2006/009134
A novel fungicide that exhibits a wide disease control spectrum against pathogenic fungi acting on various crops and helps resolve worsening resistant strain problems. There are provided diamine derivatives of the formula (1), a process ...  
WO/2006/007435
The present invention is directed to novel sulfamide and sulfamate derivatives, pharmaceutical composlons containing them and their use in the treatment of epilepsy and related disorders.  
WO/2006/007436
The present invention is directed to novel sulfamide and sulfamate derivatives, pharmaceutical compositions containing them and their use in the treatment of epilepsy and related disorders.  
WO/2006/003227
The invention relates to the synthesis of polyoxygenated nitrogen systems, comprising reactions between enamines of 1,3-dioxan-5-ones and nitroolefins. More specifically, the invention relates to the reaction between enamines having form...  

Matches 351 - 400 out of 3,567